Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  

Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial (Gautret et al., 2020)

Apr 2020  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Secondary analysis of Gautret et al. showing "modest to no impact of HCQ treatment, with more significant effects from [HCQ+AZ]".
7 meta analyses show significant improvements with hydroxychloroquine for mortality Landsteiner de Sampaio Amêndola, Risch, Risch (B), Stricker, hospitalization Landsteiner de Sampaio Amêndola, recovery Prodromos, combined death/hospitalization/cases Ladapo, and cases García-Albéniz.
Currently there are 38 HCQ for COVID-19 early treatment studies, showing 72% lower mortality [59‑81%], 67% lower ventilation [-710‑99%], 28% lower ICU admission [-17‑55%], and 41% lower hospitalization [28‑51%].
Lover et al., 10 Apr 2020, preprint, 1 author.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial
Andrew A Lover
doi:10.1101/2020.03.22.20040949
The author stands by all analytical and statistical aspects of this preprint. However, subsequent to this analysis, further details of the original study have been released-with major uncertainties in study design, reporting, choice of endpoints, and most importantly, data integrity [1, 2] . Therefore, all results from the original study should be viewed with considerable skepticism.
References
Bik, Thoughts on the Gautret et al. paper about Hydroxychloroquine and Azithromycin treatment of COVID-19 infections
Coveney, Firthlogit: Stata module to calculate bias reduction in logistic regression
Gautret, Lagier, Parola, Van Thuan, Hoang et al., Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial, medRxiv
Ian R White, Horton, Carpenter, Pocock, Strategy for intention to treat analysis in randomised trials with missing outcome data, Bmj
Lorenc, Oliver, Adverse effects of public health interventions: a conceptual framework, J Epidemiol Community Health
Mcnutt, Wu, Xue, Hafner, Estimating the relative risk in cohort studies and clinical trials of common outcomes, American journal of epidemiology
Michael A Johansson, Reich, Meyers, Lipsitch, Preprints: An underutilized mechanism to accelerate outbreak science, PLoS medicine
Nakagawa, Innes, Cuthill, Effect size, confidence interval and statistical significance: a practical guide for biologists, Biological reviews
Pubpeer, Pubpeer: Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial
Rivers, Chretien, Riley, Pavlin, Woodward et al., Using "outbreak science" to strengthen the use of models during epidemics, Nature Communications
Royston, Parmar, Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects, Statistics in medicine
Sandeep, Gupta, Intention-to-treat concept: a review, Perspectives in clinical research
Tjur, Coefficients of determination in logistic regression models-a new proposal: The coefficient of discrimination, The American Statistician
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit